1. CDC investigating cases of hospitalization after IXCHIQ vaccination. 
2. Common adverse reactions include tenderness, headache, and nausea. 
3. Chikungunya vaccine recommended for some travelers.
4. Health care providers encouraged to report adverse events through VAERS.
5.  Long-term immune response data still being collected. 
6. Vaccine seroresponse rate reported to be at least 96% for a minimum of 6 months.

Source: CDC